Menu
H

Health Research of Hampton Roads, Inc. | Newport News, VA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Orforglipron
MK-0616
Galcanezumab
Tirzepatide
LY3502970
LY3298176
Diclofenac Sodium Gel
Atogepant
Canakinumab
Vibegron

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Active trials

The GZPL master protocol will support 2 independent studies, J2A-MC-GZL1 (GZL1) and J2A-MC-GZL2 (GZL2). The purpose of this study is to create a fram...

Not yet enrolling
Hypertension
Drug: Orforglipron
Drug: Placebo

GZL1 is an independent study conducted under the GZPL master protocol. GZL1 will evaluate the efficacy and safety of orforglipron for treatment of hy...

Not yet enrolling
Hypertension
Overweight or Obesity
Drug: Placebo
Drug: Orforglipron

GZL2 is an independent study conducted under the GZPL master protocol. GZL2 study will evaluate the efficacy and safety of orforglipron for treatment...

Not yet enrolling
Hypertension
Drug: Orforglipron
Drug: Placebo

This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the treatme...

Enrolling
Acute Migraine
Drug: Placebo
Drug: Elismetrep (K-304) Dose level 3

The goal of this study is to evaluate the efficacy, safety, and tolerability of enlicitide decanoate in adult participants with heterozygous familial...

Active, not recruiting
Hypercholesterolemia
Familial Hypercholesterolemia
Drug: Placebo
Drug: Enlicitide Decanoate

The goal of this study is to evaluate the efficacy, safety, and tolerability of enlicitide decanoate in adult participants with hypercholesterolemia....

Active, not recruiting
Hypercholesterolemia
Familial Hypercholesterolemia
Drug: Enlicitide Decanoate
Drug: Placebo

The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1010, and to evaluate relative vaccine efficacy (rVE) of m...

Enrolling
Seasonal Influenza
Biological: Fluarix Tetra
Biological: Fluarix®

This study will investigate the efficacy and safety of once daily oral orforglipron in adult participants with obesity or overweight with weight-rela...

Active, not recruiting
Overweight or Obesity
Overweight
Drug: Placebo
Drug: Orforglipron

The main purpose of Part A of this study is to evaluate the safety and tolerability of mRNA-1345 vaccine and to demonstrate the efficacy of a single...

Active, not recruiting
Respiratory Syncytial Virus
Drug: Placebo
Drug: mRNA-1345

The primary objective of the study is to determine the relative efficacy of the investigational oral severe acute respiratory syndrome coronavirus 2...

Active, not recruiting
COVID-19
SARS-CoV2
Biological: VXA-CoV2-3.1
Biological: COMIRNATY®

The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1403, and to demonstrate the efficacy of mRNA-1403 to prev...

Enrolling
Acute Gastroenteritis
Norovirus Acute Gastroenteritis
Biological: mRNA-1403
Biological: Placebo

This study is researching experimental drugs called trevogrumab and garetosmab (called "study drugs") in combination with another drug, semaglutide (...

Active, not recruiting
Obesity
Drug: Matching Placebo-Trevogrumab
Drug: Matching Placebo-Garetosmab

The purpose of this study is to evaluate the efficacy, immunogenicity and safety of the 9vHPV vaccine in men 20 to 45 years of age. The primary hypot...

Active, not recruiting
Papillomavirus Infections
Biological: 9vHPV Vaccine
Other: Placebo (Saline for Injection)

This is a phase 3, randomized, placebo-controlled study of the efficacy and safety of enlicitide decanoate, an oral proprotein convertase subtilisin/...

Enrolling
Arteriosclerosis
Hypercholesterolaemia
Drug: Placebo
Drug: Enlicitide Decanoate
Locations recently updated

The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.

Enrolling
Obesity
Drug: Placebo
Drug: Maridebart Cafraglutide

This is an extension study to evaluate the longer-term safety and efficacy of enlicitide decanoate in adults with hypercholesterolemia who completed...

Enrolling
Hypercholesterolemia
Drug: Enlicitide Decanoate

Safety assessment of long-term 3 mg cytisinicline three times daily (TID) exposure for 52 weeks is the main purpose of this study, conducted in the U...

Active, not recruiting
Vaping Cessation
Smoking Cessation
Drug: Cytisinicline
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trial sponsors

Lilly logo
Merck Sharp & Dohme (MSD) logo
Moderna logo
Novartis logo
Novavax logo
Pfizer logo
Allergan logo
K
Merz Pharmaceuticals logo
N